Data Sheet (Cat.No.T61360)

TargetMol

ARN25068

Chemical Properties



CAS No. : 2649882-80-2

Formula: C19H18N6S

Molecular Weight: 362.45

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	ARN25068 is a potent inhibitor of GSK-3β, FYN, and DYRK1A protein kinases, exerting its activity in the sub-micromolar range. This compound effectively addresses tau hyperphosphorylation [1].
Targets(IC50)	Microtubule Associated,DYRK,GSK-3,Src
In vitro	ARN25068 diminishes tau phosphorylation levels in the Tau0N4R-TM-tGFP U2OS cell line. [1]

Solubility Information

Solubility	DMSO: 55 mg/mL (151.75 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (13.8 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.759 mL	13.795 mL	27.590 mL
5 mM	0.5518 mL	2.759 mL	5.518 mL
10 mM	0.2759 mL	1.3795 mL	2.759 mL
50 mM	0.0552 mL	0.2759 mL	0.5518 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Demuro S, et al. ARN25068, a versatile starting point towards triple GSK-3β/FYN/DYRK1A inhibitors to tackle tau-related neurological disorders. Eur J Med Chem. 2022;229:114054.
Lindberg MF, et al. Comparative Efficacy and Selectivity of Pharmacological Inhibitors of DYRK and CLK Protein Kinases. J Med Chem. 2023;66(6):4106-4130.